SBIOvsXBIETF Comparison
VS
ALPS Medical Breakthroughs ETF (SBIO) belongs to the Tomorrow's Treatments segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. SBIO's top 2 sector exposures are Healthcare and Non-Corporate. In contrast, XBI's top sector exposures are Healthcare and Finance. SBIO is more expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.35% for XBI. SBIO is up 5.07% year-to-date (YTD) with +$61M in YTD flows. XBI performs better with 23.54% YTD performance, and +$631M in YTD flows. Run a side-by-side ETF comparison of SBIO and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
SBIO vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/26/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | SBIO XBI | -7.93%-3.86% | -16.56%+0.01% | +5.07%+23.54% | +21.15%+35.47% | +130.34%+128.86% | +20.79%+22.21% |
| Flows | SBIO XBI | -$11M+$311M | +$20M+$237M | +$61M+$631M | +$93M+$1.09B | +$44M-$158M | +$5M+$1.66B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | SBIO XBI | +32.02%+30.50% | +32.11%+28.93% | +31.51%+28.42% | +34.22%+33.06% |
| Max drawdown | SBIO XBI | -29.19%-14.89% | -29.19%-14.89% | -42.12%-32.94% | -52.50%-53.28% |
| Max drawdown duration | SBIO XBI | 68d68d | 68d68d | 331d331d | 1479d1622d |
Trading data
SBIO | XBI | |
Last sale 10/27/2026 at 1:30 PM | $55.48 | $154.84 |
| Previous close 10/26/2026 | $53.78 | $150.47 |
| Consolidated volume 10/26/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
SBIO | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/27/2026 at 1:30 PM
Live
Closed
SBIO | XBI | |
|---|---|---|
| Last price | $55.48 | $154.84 |
| 1D performance | +3.16% | +2.90% |
| AuM | $183.99 M | $10.20 B |
| E/R | 0.5% | 0.35% |
Characteristics
SBIO | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | ALPS | State Street Investment Management |
| Benchmark | S-Network Medical Breakthroughs Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 104 | 149 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 30, 2014 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
SBIO
USA
89.31%
Other
10.69%
XBI
USA
95.53%
Other
4.47%
Sectors
SBIO
Healthcare
100.01%
Other
-0.01%
XBI
Healthcare
99.18%
Other
0.82%
Advertisement
Diversification
SBIO
Total weight of top 15 holdings out of 15
41.55%
XBI
Total weight of top 15 holdings out of 15
21.91%
Top 15 holdings
Data as of August 31, 2026
SBIO
Crinetics Pharmaceuticals, Inc.
4.60%
Apogee Therapeutics, Inc.
4.29%
CG Oncology, Inc.
3.41%
Travere Therapeutics, Inc.
3.16%
Xenon Pharmaceuticals, Inc.
2.99%
Dianthus Therapeutics, Inc.
2.96%
Oruka Therapeutics, Inc.
2.87%
ACADIA Pharmaceuticals, Inc.
2.54%
Edgewise Therapeutics, Inc.
2.31%
Definium Therapeutics, Inc.
2.23%
Dyne Therapeutics, Inc.
2.16%
Veradermics, Inc.
2.11%
Relay Therapeutics, Inc.
2.05%
Denali Therapeutics, Inc.
1.94%
Amylyx Pharmaceuticals, Inc.
1.93%
XBI
Moderna, Inc.
2.81%
Twist Bioscience Corp.
1.89%
Apogee Therapeutics, Inc.
1.50%
Kymera Therapeutics, Inc.
1.40%
Halozyme Therapeutics, Inc.
1.39%
Natera, Inc.
1.37%
Praxis Precision Medicines, Inc.
1.34%
Oruka Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.31%
Travere Therapeutics, Inc.
1.30%
Protagonist Therapeutics, Inc.
1.28%
Dianthus Therapeutics, Inc.
1.27%
CG Oncology, Inc.
1.26%
Vaxcyte, Inc.
1.23%
Erasca, Inc.
1.23%
Frequently asked questions about SBIO and XBI
How have the SBIO and XBI ETFs performed in 2026?
As of October 26, 2026, SBIO is up 5.07% year-to-date (YTD), while XBI has returned 23.54%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: SBIO or XBI?
Year-to-date, the SBIO ETF saw +$61M in flows, compared to +$631M for XBI.
Which ETF is more volatile: SBIO or XBI?
Over the past year, SBIO had a volatility of 32.11%, while XBI experienced 28.93%.
Which ETF is bigger: SBIO or XBI?
As of October 26, 2026, SBIO holds $183.99 M in assets under management (AUM), while XBI manages $10.20 B.
What sectors do the SBIO and XBI ETFs invest in?
SBIO leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the SBIO ETF and XBI ETF?
SBIO top holdings include Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc.. XBI holds in its top three: Moderna, Inc., Twist Bioscience Corp. and Apogee Therapeutics, Inc..
Which ETF is more diversified: SBIO or XBI?
SBIO holds 104 securities with 41.55% of its assets in the top 15. XBI has 152 securities and a top 15 weight of 21.91%.
Advertisement
Latest news about SBIO & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
